Infectious disease treatment: A breakthrough in personalized medicine

Science and Health

Personalized medicine is an emerging field of medicine that uses an individual’s genetic profile to guide decisions made for the prevention, diagnosis and treatment of disease. It exists today in a subset of diseases such as cancer, but there is almost no use of personal medicine tools in the field of infectious diseases. 

Based on their scientific “breakthrough,” researchers at Tel Aviv University (TAU) believe it will be possible in the future to apply personalized medicine to infectious diseases and provide more effective treatments for patients.

An infectious disease is a condition in which a microorganism – bacterium, virus or parasite – manages to enter and multiply in the human body, causing direct damage to the body’s cells. The damage to the body may also be indirect, as a result of the reaction of the immune system such as the creation of inflammation against the same disease-causing agent (pathogen). 

Unveiling the dual components of the immune response

Until now, the medical world studied the immune response as a single unit, but the TAU team discovered a way, using experiments and computational tools, to classify two central components of the immune response that operate as a result of severe infectious disease. 

They said the importance of the discovery is that it provides a doorway to the world of personalized medicine in the field of infectious diseases and the provision of more effective treatments for patients. For example, instead of deciding to give a uniform medicine to all patients such as an antibiotic like penicillin, the physician will be able to know precisely which medicine he should give the patient and at what dosage, according to the classification of the infection based on analysis of the ratio between two key markers found in the patient’s blood. 

Professor Eran Bachrach (credit: TEL AVIV UNIVERSITY)

They used transcriptional and physiological monitoring across 33 mouse strains, during in vivo influenza virus infection, to identify two host-defense gene programs, one associated with hallmarks of disease tolerance and the other with hallmarks of resistance. 

Breakthrough research expands personalized medicine in infectious diseases 

The research was led by Prof. Irit Gat-Viks and Prof. Eran Bacharach, with the doctoral students Ofir Cohn and Gal Yankovitz from TAU’s Shmunis School of Biomedicine and Cancer Research in the George S. Wise Faculty of Life Sciences. The study has just been published in the prestigious journal Cell Systems” under the title “Distinct gene programs underpinning disease tolerance and resistance in influenza virus infection.” 

Gat-Viks explained that in the general population, “people react differently to infections, so there is a need for medical tools to indicate how each person is expected to respond to a certain infectious disease. Until now, there have been only very general indicators to characterize these diseases, such as inflammatory markers, fever, urine tests and the like. Based on these indicators, analyses of the response to the infection that appeared rather uniform can be divided into different responses according to the new classification.”

Professor Irit Gat-Viks (credit: YOEL ANDA)

She continued that “in fact, personalized medicine exists today for ‘regular’ diseases such as cancer, but there is almost no use of personalized medicine methods in the field of infectious diseases. People with extreme reactions to infection with microorganisms such as viruses or bacteria lack an adequate medical response today. We believe that thanks to our research, doctors will be able to better diagnose the patient’s condition and, as a result, provide effective treatment that will improve the patient’s chances of recovery. We aim to continue the research and discover more subgroups with different reactions among the population so that we can help doctors make their diagnosis more precise and thus provide proper treatment for their patients.” 

In extreme cases, as occurred in the COVID-19 pandemic, a person’s immune response to the virus “can result in lethality, and preliminary identification of their response can help us save lives. Our new observations and more precise classification of the inflammatory response has allowed us to identify new indicators and markers in our bloodstream. What all this means is that from simple blood tests, we can learn a lot about the health status of people who became ill and give them more comprehensive treatment according to the development of the infection in their bodies,” they wrote.

Bacharach concluded that “we were able to observe the response of the immune system with high resolution and identify two main types of responses – one, in which the immune system fights a pathogen that has entered the body; and the other type, in which the damage to the body “after the war” with the pathogen is repaired. In our research, we used disease models in animals, computational tools and data collected from people with different markers in their bodies that are indicators of the type of response to the pathogen.”